


HX630

Cat. No.:	HY-108520
CAS No.:	188844-52-2
Molecular Formula:	C ₂₈ H ₂₇ NO ₂ S
Molecular Weight:	441.58
Target:	RAR/RXR; Apoptosis
Pathway:	Metabolic Enzyme/Protease; Vitamin D Related/Nuclear Receptor; Apoptosis
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.



BIOLOGICAL ACTIVITY

Description	HX630 is a potent retinoic acid X receptor (RXR) agonist, can induce apoptosis, has anti-tumor effect, and can be used in Cushing's disease research ^[1] .									
In Vitro	<p>HX630 (0.1-10 μM, 96 h) can dose-dependently inhibit cell proliferation and induce apoptosis of AtT20 cells^[1]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p> <p>Cell Viability Assay^[1]</p> <table border="1"> <tr> <td>Cell Line:</td> <td>AtT20 cells</td> </tr> <tr> <td>Concentration:</td> <td>0.1, 1, 5, 10 μM</td> </tr> <tr> <td>Incubation Time:</td> <td>96 h</td> </tr> <tr> <td>Result:</td> <td>Significantly inhibited AtT20 cell proliferation at 10 μM. Decreased Pomc mRNA expression and ACTH secretion in a dose-dependent manner.</td> </tr> </table>		Cell Line:	AtT20 cells	Concentration:	0.1, 1, 5, 10 μM	Incubation Time:	96 h	Result:	Significantly inhibited AtT20 cell proliferation at 10 μM. Decreased Pomc mRNA expression and ACTH secretion in a dose-dependent manner.
Cell Line:	AtT20 cells									
Concentration:	0.1, 1, 5, 10 μM									
Incubation Time:	96 h									
Result:	Significantly inhibited AtT20 cell proliferation at 10 μM. Decreased Pomc mRNA expression and ACTH secretion in a dose-dependent manner.									
In Vivo	<p>HX630 (5 mg/kg, intraperitoneal injection, 3 times a week for 3 weeks) can reduce tumor growth in BALB/c-nu mouse model infected with AtT20 cells^[1]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p> <table border="1"> <tr> <td>Animal Model:</td> <td>Female BALB/c-nu mice (nu/nu) with AtT20 cells^[1]</td> </tr> <tr> <td>Dosage:</td> <td>5 mg/kg</td> </tr> <tr> <td>Administration:</td> <td>i.p., 3 times a week for 3 weeks</td> </tr> <tr> <td>Result:</td> <td>Significantly reduced tumor volume and Pomc mRNA expression in tumor cells, but body weight and plasma ACTH levels were not significantly different.</td> </tr> </table>		Animal Model:	Female BALB/c-nu mice (nu/nu) with AtT20 cells ^[1]	Dosage:	5 mg/kg	Administration:	i.p., 3 times a week for 3 weeks	Result:	Significantly reduced tumor volume and Pomc mRNA expression in tumor cells, but body weight and plasma ACTH levels were not significantly different.
Animal Model:	Female BALB/c-nu mice (nu/nu) with AtT20 cells ^[1]									
Dosage:	5 mg/kg									
Administration:	i.p., 3 times a week for 3 weeks									
Result:	Significantly reduced tumor volume and Pomc mRNA expression in tumor cells, but body weight and plasma ACTH levels were not significantly different.									

REFERENCES

[1]. Akiko Saito-Hakoda, et al. Effects of RXR Agonists on Cell Proliferation/Apoptosis and ACTH Secretion/Pomc Expression. PLoS One. 2015 Dec 29;10(12):e0141960.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA